By detecting the number of PSA (prostate-specific antigen)-positive EVs and PSA levels in the serum, it is possible to differentiate between patients with prostate cancer and those with benign prostatic hyperplasia. In addition, the accuracy of prostate cancer diagnosis can be improved by detecting tumor-specific markers in EVs. The gene discussed is KLK3; the disease is prostate carcinoma.